Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5 Oncol Ther (2017) 5:31–40 DOI 10.1007/s40487-016-0037-8 ORIGINAL RESEARCH The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5 . . . Steve Schey Luis Felipe Casado Montero Chloe Stengel-Tosetti Craig J. Gibson Sujith Dhanasiri Received: October 24, 2016 / Published online: January 3, 2017 The Author(s) 2016. This article is published with open access at Springerlink.com on treatment duration and time to progression ABSTRACT (TTP) (taken from trial data). We compared a Introduction: Lenalidomide is an active agent baseline scenario (of current lenalidomide that was approved for use in the EU in 2015 as a uptake) with two alternative future scenarios. first-line therapy for previously untreated, Future Scenario A used an increased uptake of non-transplant eligible multiple myeloma first-line lenalidomide: up to 50% in Year 5. patients. Our objective was to assess the cost Future Scenario B was similar to the baseline, impact of lenalidomide when selected as a but included a 20% increased uptake of the first-line treatment for transplant-ineligible triple therapy regimen, carfilzomib, patients in France, Germany, Italy, Spain, and lenalidomide, and dexamethasone (KRd) at the United Kingdom (EU5). second line. Methods: We developed a cost-impact model of Results: Compared to alternative first-line care http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5

Download PDF
10 pages

Loading next page...
 
/lp/springer-journals/the-cost-impact-of-lenalidomide-for-newly-diagnosed-multiple-myeloma-0C0G12YD4a
Publisher
Springer Journals
Copyright
Copyright © 2016 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-016-0037-8
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2017) 5:31–40 DOI 10.1007/s40487-016-0037-8 ORIGINAL RESEARCH The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5 . . . Steve Schey Luis Felipe Casado Montero Chloe Stengel-Tosetti Craig J. Gibson Sujith Dhanasiri Received: October 24, 2016 / Published online: January 3, 2017 The Author(s) 2016. This article is published with open access at Springerlink.com on treatment duration and time to progression ABSTRACT (TTP) (taken from trial data). We compared a Introduction: Lenalidomide is an active agent baseline scenario (of current lenalidomide that was approved for use in the EU in 2015 as a uptake) with two alternative future scenarios. first-line therapy for previously untreated, Future Scenario A used an increased uptake of non-transplant eligible multiple myeloma first-line lenalidomide: up to 50% in Year 5. patients. Our objective was to assess the cost Future Scenario B was similar to the baseline, impact of lenalidomide when selected as a but included a 20% increased uptake of the first-line treatment for transplant-ineligible triple therapy regimen, carfilzomib, patients in France, Germany, Italy, Spain, and lenalidomide, and dexamethasone (KRd) at the United Kingdom (EU5). second line. Methods: We developed a cost-impact model of Results: Compared to alternative first-line care

Journal

Oncology and Therapy – Springer Journals

Published: Jan 3, 2017

References

  • Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
    Moreau, P; San Miguel, J; Ludwig, H
  • Can we change the disease biology of multiple myeloma?
    Borrello, I
  • Frontline therapy of multiple myeloma
    Moreau, P; Attal, M; Facon, T
  • Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma
    Benboubker, L; Dimopoulos, MA; Dispenzieri, A
  • A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation
    Weisel, K
  • Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma
    Arikian, SR; Milentijevic, D; Binder, G
  • Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study
    Armoiry, X; Fagnani, F; Benboubker, L
  • Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents
    Gaultney, JG; Franken, MG; Tan, SS
  • Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
    San Miguel, JF; Schlag, R; Khuageva, NK
  • Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial
    Kropff, M; Baylon, HG; Hillengass, J
  • Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
    Richardson, PG; Sonneveld, P; Schuster, MW
  • Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
    Stadtmauer, EA; Weber, DM; Niesvizky, R
  • Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib
    Sood, R; Carloss, H; Kerr, R